Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen : Alliance Global Partners Adjusts Price Target on OpGen to $7 From $5.65, Maintains Buy Rating

03/02/2021 | 11:11am EDT


ę MT Newswires 2021
All news about OPGEN, INC.
07/30SUPERNUS PHARMACEUTICALS : Pharma Says Named New CFO After Incumbent Resigned to..
MT
07/29OPGEN INC : Change in Directors or Principal Officers (form 8-K)
AQ
07/29Opgen, Inc. Announces Resignation of Timothy C. Dec as Corporate Secretary, E..
CI
07/07OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/07OpGen Announces Partial Adjournment of Annual Meeting
GL
06/30OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AM..
GL
06/28OpGen Group Company Ares Genetics Presents R&D Pipeline Updates
GL
06/25OPGEN, INC.(NASDAQCM : OPGN) dropped from Russell 3000E Growth Index
CI
06/25OPGEN, INC.(NASDAQCM : OPGN) dropped from Russell Microcap Growth Index
CI
06/15OPGEN : Thinking about buying stock in Ocugen, Rapt Therapeutics, ContextLogic, ..
PR
More news
Financials (USD)
Sales 2021 7,79 M - -
Net income 2021 -35,6 M - -
Net Debt 2021 3,78 M - -
P/E ratio 2021 -2,66x
Yield 2021 -
Capitalization 100 M 100 M -
EV / Sales 2021 13,4x
EV / Sales 2022 5,43x
Nbr of Employees 102
Free-Float 99,8%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 2,62 $
Average target price 5,50 $
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.28.43%100
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.03%47 462
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-11.93%27 907